Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQB 3602

Next Previous
Drug Profile

TQB 3602

Alternative Names: TQB-3602

Latest Information Update: 28 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Multiple myeloma

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for phase-I development in Multiple-myeloma(Late-stage disease, Second-line therapy or greater) in China (PO, Capsule)
  • 17 Jan 2023 Chia Tai Tianqing Pharmaceutical Group completes enrollment of a phase I trial in Multiple myeloma (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT04275583)
  • 10 Dec 2022 Updated efficacy, safety and pharmacokinetics data from a phase I trial in Multiple myeloma presented at 64th American Society of Hematology Annual Meeting and Exposition (ASH-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top